Dominic Millenaar

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/986765/publications.pdf

Version: 2025-02-01

260 peer-reviewed articles	26,220 peer-reviewed citations	22242 59 peer-reviewed h-index	254571 4.93 score
296 documents	29562 doc citations	20543 65 h-index	43025 citing authors

#	Article	IF	Citations
1	SAFETY AND EFFICACY OF RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH PRIOR STROKE: 3-YEAR RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY. Journal of Hypertension, 2025, 43, e195-e196.	1.8	0
2	O89 POOLED, LONG-TERM ANALYSIS OF THE GLOBAL SYMPLICITY CLINICAL TRIAL PROGRAM OF RADIOFREQUENCY RENAL DENERVATION FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION. Journal of Hypertension, 2024, 42, e41.	1.8	0
3	O91 SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS FOLLOWING RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS FROM THE SPYRAL HTN TRIALS. Journal of Hypertension, 2024, 42, e42.	1.8	0
4	Fifty Years of Global Cardiovascular Research in Africa: A Scientometric Analysis, 1971 to 2021. Journal of the American Heart Association, 2023, 12, .	3.1	17
5	“General knowledge on arterial hypertension” of the DGK. Die Kardiologie, 2023, 18, 49-52.	0.7	0
6	Arterial hypertension – Clinical trials update 2021. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 21-31.	2.1	90
7	Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial. Cardiovascular Revascularization Medicine, 2022, 39, 58-65.	0.4	9
8	Sex Differences in Cardiovascular Research: A Scientometric Analysis. Journal of the American Heart Association, 2022, 11, .	3.1	8
9	Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation. Scientific Reports, 2022, 12, .	2.7	10
10	Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD. Circulation Research, 2022, 130, 814-828.	8.6	30
11	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. Clinical Research in Cardiology, 2022, 111, 806-815.	1.5	18
12	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clinical Research in Cardiology, 2022, 112, 197-202.	1.5	27
13	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	13.1	76
14	Photoinduced skin reactions of cardiovascular drugs—a systematic review. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 420-430.	2.6	19
15	Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization. PLoS ONE, 2022, 17, e0266069.	1.5	2
16	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet, The, 2022, 399, 1401-1410.	46.9	279
17	Effects of Medical Face Masks on Physical Performance in Patients With Coronary Artery Disease or Hypertension. American Journal of Cardiology, 2022, 173, 1-7.	1.5	6
18	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. Circulation: Cardiovascular Interventions, 2022, 15, .	3.2	68

#	Article	IF	Citations
19	Heart-Focused Anxiety, General Anxiety, Depression and Health-Related Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation. Journal of Clinical Medicine, 2022, 11, 1751.	1.8	16
20	Ischemic Stroke—A Scientometric Analysis. Frontiers in Neurology, 2022, 13, .	1.6	7
21	Arterial hypertension - clinical trials update 2022. Hypertension Research, 2022, 45, 1140-1146.	2.0	4
22	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension, 2022, 79, 1506-1514.	4.7	21
23	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.6	19
24	Cardio-renal interaction - Clinical trials update 2022. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2451-2458.	2.1	6
25	A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling. Pharmaceutics, 2022, 14, 1474.	4.2	15
26	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	0.7	72
27	Inhibition of TRIF-Dependent Inflammation Decelerates Afterload-Induced Myocardial Remodeling. Biomedicines, 2022, 10, 2636.	2.5	1
28	Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 242-250.	2.6	45
29	Registration of Image Modalities for Analyses of Tissue Samples Using 3D Image Modelling. Proteomics - Clinical Applications, 2021, 15, .	1.5	4
30	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter. Cardiovascular Revascularization Medicine, 2021, 24, 77-86.	0.4	6
31	Myocardial infarction in a patient with single coronary artery - rare but real. Journal of Cardiology Cases, 2021, 23, 246-249.	0.3	2
32	Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2021, 14, .	3.8	39
33	Valvular heart disease in patients with chronic kidney disease. Herz, 2021, 46, 228-233.	0.8	21
34	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension, 2021, 39, 766-774.	1.8	11
35	One year results of the first in man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. European Journal of Heart Failure, 2021, 23, 800-810.	5.0	71
36	The current status of renal denervation for the treatment of arterial hypertension. Progress in Cardiovascular Diseases, 2021, 65, 76-83.	4.9	18

#	Article	IF	Citations
37	Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis. Molecules, 2021, 26, 1495.	3.2	11
38	Kardiovaskuläre Forschung in Deutschland 2020 – eine szientometrische Analyse. Kardiologe, 2021, 15, 160-167.	0.2	0
39	Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 667-676.	0.8	11
40	Arterielle Hypertonie – Was war 2020 wichtig?. Kardiologe, 2021, 15, 127-132.	0.2	1
41	Device Therapy of Hypertension. Circulation Research, 2021, 128, 1080-1099.	8.6	57
42	Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis. Journal of Cardiovascular Electrophysiology, 2021, 32, 1430-1439.	1.6	13
43	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. Journal of Human Hypertension, 2021, 36, 629-639.	1.4	34
44	Extra-Cardiac Targets in the Management of Cardiometabolic Disease: Device-Based Therapies. ESC Heart Failure, 2021, 8, 3327-3338.	1.9	4
45	Effects of face masks on performance and cardiorespiratory response in well-trained athletes. Clinical Research in Cardiology, 2021, 111, 264-271.	1.5	31
46	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	0.7	108
47	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). American Journal of Cardiology, 2021, 149, 27-35.	1.5	22
48	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet, The, 2021, 397, 2476-2486.	46.9	403
49	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	1.8	126
50	Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“ – Update. Kardiologe, 2021, 15, 463-470.	0.2	7
51	Mapping of an atrial tachycardia after Epicor™ high-intensity focused ultrasound ablation: A case report. Journal of Electrocardiology, 2021, 67, 19-22.	0.6	0
52	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine, 2021, 385, 1643-1655.	26.4	552
53	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.	13.1	76
54	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Journal of the American College of Cardiology, 2021, 78, 1028-1038.	0.7	54

#	Article	IF	Citations
55	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. Contemporary Clinical Trials Communications, 2021, 23, 100818.	0.9	8
56	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. American Heart Journal, 2021, 239, 90-99.	1.8	25
57	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, .	3.2	15
58	Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. Catheterization and Cardiovascular Interventions, 2021, 98, .	1.1	2
59	Hypertension trials update. Journal of Human Hypertension, 2021, 35, 398-409.	1.4	14
60	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2021, 23, 1960-1970.	5.0	23
61	Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS. Analytica Chimica Acta, 2021, 1187, 339137.	4.4	12
62	Update Hypertonie: Fokus auf die renale Denervation. Kardiologie Up2date, 2021, 17, 337-352.	0.0	0
63	The Current Status of Devices for the Treatment of Resistant Hypertension. American Journal of Hypertension, 2020, 33, 10-18.	1.0	11
64	Invasive left ventricle pressure–volume analysis: overview and practical clinical implications. European Heart Journal, 2020, 41, 1286-1297.	2.6	227
65	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.6	6,388
66	Risk prediction with blood pressure during physical activity: A METter of exercise?. European Journal of Preventive Cardiology, 2020, 27, 975-977.	1.5	1
67	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet, The, 2020, 396, 1504-1510.	46.9	262
68	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. European Heart Journal, 2020, 41, 2556-2569.	2.6	24
69	Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth. Vascular Pharmacology, 2020, 127, 106661.	1.2	12
70	A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model. Clinical Research in Cardiology, 2020, 111, 595-603.	1.5	7
71	J-curve revisited. European Heart Journal, 2020, 41, 4283-4283.	2.6	0
72	Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure. European Heart Journal, 2020, 41, 4600-4600.	2.6	1

#	Article	IF	Citations
73	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. Clinical Research in Cardiology, 2020, 109, 1500-1506.	1.5	77
74	Research in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 1008-1018.	2.4	11
75	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. Journal of Human Hypertension, 2020, 35, 903-911.	1.4	23
76	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. Journal of Clinical Hypertension, 2020, 22, 1807-1816.	1.6	7
77	Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics, 2020, 12, 1200.	4.2	21
78	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2922-2933.	1.9	65
79	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. European Heart Journal, 2020, 41, 2848-2859.	2.6	34
80	Renal Denervation in High-Risk Patients With Hypertension. Journal of the American College of Cardiology, 2020, 75, 2879-2888.	0.7	117
81	Wissenschaftslandschaft Deutschland. Kardiologe, 2020, 14, 113-123.	0.2	3
82	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet, The, 2020, 395, 1444-1451.	46.9	567
83	Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. Journal of the American Heart Association, 2020, 9, .	3.1	15
84	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Research in Cardiology, 2020, 109, 1507-1509.	1.5	0
85	Changes in Stroke Volume After Renal Denervation. Hypertension, 2020, 75, 707-713.	4.7	16
86	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. European Heart Journal, 2020, 41, 1673-1683.	2.6	57
87	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 471-484.	1.9	99
88	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Clinical Research in Cardiology, 2020, 109, 289-302.	1.5	40
89	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	0.7	112
90	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. JACC: Case Reports, 2020, 2, 384-388.	0.2	3

#	Article	IF	Citations
91	Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. European Heart Journal, 2020, 41, 1588-1599.	2.6	91
92	Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. Journal of Hypertension, 2020, 38, 783-790.	1.8	29
93	Renal Denervation in Daily Practice: If So, How?. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 267-270.	1.4	2
94	Device-based therapies for arterial hypertension. Nature Reviews Cardiology, 2020, 17, 614-628.	25.1	115
95	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. Clinical Research in Cardiology, 2020, 110, 725-731.	1.5	29
96	Where is renal nerve ablation going?. European Heart Journal, 2020, 41, 4538-4540.	2.6	2
97	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	4.7	45
98	ESC Council on hypertension position document on the management of hypertensive emergencies. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 37-46.	2.6	242
99	Ventricular arrhythmias and myocardial inflammation: Long-term follow-up of patients with suspected myocarditis. International Journal of Cardiology, 2019, 274, 132-137.	1.6	28
100	Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy. Hypertension, 2019, 74, 546-554.	4.7	25
101	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension, 2019, 74, 244-249.	4.7	27
102	Renal Denervation for Treating Hypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	1.9	83
103	Renal Denervation: Is It Ready for Prime Time?. Current Cardiology Reports, 2019, 21, .	2.3	12
104	Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz. Herz, 2019, 44, 611-629.	0.8	2
105	Looking back and thinking forwards — 15 years of cardiology and cardiovascular research. Nature Reviews Cardiology, 2019, 16, 651-660.	25.1	17
106	Renal Denervation Update From the International Sympathetic Nervous System Summit. Journal of the American College of Cardiology, 2019, 73, 3006-3017.	0.7	101
107	Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects. American Journal of Hypertension, 2019, 32, 935-937.	1.0	0
108	Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. Analytica Chimica Acta, 2019, 1070, 69-79.	4.4	24

#	Article	IF	Citations
109	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	13.1	117
110	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.6	285
111	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal, 2019, 40, 2032-2043.	2.6	66
112	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. Journal of the American Heart Association, 2019, 8, .	3.1	43
113	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension. Journal of Hypertension, 2019, 37, 1906-1912.	1.8	21
114	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. American Heart Journal, 2019, 209, 97-105.	1.8	62
115	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. European Heart Journal, 2019, 40, 743-751.	2.6	84
116	Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension. Clinical Research in Cardiology, 2019, 109, 581-588.	1.5	13
117	Herzklappenvitien bei chronischer Niereninsuffizienz. Der Internist, 2019, 61, 368-374.	0.4	2
118	Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach. Clinical Research in Cardiology, 2019, 109, 810-818.	1.5	17
119	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clinical Research in Cardiology, 2019, 109, 845-856.	1.5	33
120	Renal denervation: dark past, bright future?. Cardiovascular Journal of Africa, 2019, 30, 290-296.	0.2	4
121	Update kardiorenales Syndrom. Aktuelle Kardiologie, 2019, 8, 467-474.	0.0	0
122	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. Cardiovascular Revascularization Medicine, 2018, 19, 845-851.	0.4	14
123	Real-time left ventricular pressure–volume loops during percutaneous central arteriovenous anastomosis. European Heart Journal, 2018, 39, 2330-2331.	2.6	8
124	Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. Clinical Autonomic Research, 2018, 28, 375-384.	1.6	26
125	The association between different features of sleep-disordered breathing and blood pressure: A cross-sectional study. Journal of Clinical Hypertension, 2018, 20, 575-581.	1.6	23
126	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. Clinical Research in Cardiology, 2018, 107, 642-652.	1.5	22

#	Article	IF	Citations
127	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	1.8	77
128	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. Journal of Hypertension, 2018, 36, 2453-2459.	1.8	15
129	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	1.2	724
130	Twenty-Four–Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 2018, 138, 1602-1604.	13.1	52
131	Catheter-based renal denervation: the next chapter begins. European Heart Journal, 2018, 39, 4144-4149.	2.6	21
132	European Society of Hypertension position paper on renal denervation 2018. Journal of Hypertension, 2018, 36, 2042-2048.	1.8	44
133	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	46.9	758
134	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	46.9	706
135	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.6	9,097
136	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet, The, 2018, 392, 849-856.	46.9	459
137	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. European Heart Journal, 2018, 39, 3105-3114.	2.6	120
138	Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. Clinical Research in Cardiology, 2018, 108, 574-576.	1.5	4
139	Will ORBITA change my practice? ORBITA trial: Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina. EuroIntervention, 2018, 14, 951-954.	2.2	1
140	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. European Heart Journal, 2017, , ehw325.	2.6	109
141	Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. Europace, 2017, , euw092.	1.8	48
142	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. International Journal of Cardiology, 2017, 241, 373-378.	1.6	25
143	Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. European Heart Journal, 2017, 38, 3272-3281.	2.6	113
144	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry. Journal of Clinical Hypertension, 2017, 19, 833-839.	1.6	16

#	Article	IF	Citations
145	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet, The, 2017, 389, 2226-2237.	46.9	310
146	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. Journal of the American Heart Association, 2017, 6, .	3.1	69
147	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. International Journal of Cardiology, 2017, 249, 365.	1.6	3
148	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	46.9	723
149	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. Current Vascular Pharmacology, 2017, 16, .	1.5	7
150	Target blood pressure in high risk cardiovascular patients. Journal of Thoracic Disease, 2017, 9, E877-E878.	0.9	0
151	Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment?. EuroIntervention, 2017, 12, e2163-e2165.	2.2	0
152	Non-Adherence to Ivabradine and Placebo and Outcomes in Chronic Heart Failure: An Analysis from SHIFT. European Journal of Heart Failure, 2016, 18, 672-683.	5.0	24
153	Device-based Therapy for Hypertension. Current Hypertension Reports, 2016, 18, .	3.5	42
154	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. Journal of the American Heart Association, 2016, 5, .	3.1	22
155	Impact of obstructive and central apneas on ventricular repolarisation: lessons learned from studies in man and pigs. Clinical Research in Cardiology, 2016, 105, 639-647.	1.5	25
156	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clinical Research in Cardiology, 2016, 105, 873-879.	1.5	72
157	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. Journal of Hypertension, 2016, 34, 1854-1862.	1.8	22
158	Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats. Journal of Translational Medicine, 2016, 14, .	4.8	12
159	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. American Heart Journal, 2016, 171, 82-91.	1.8	155
160	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. Journal of the American College of Cardiology, 2015, 66, 1766-1775.	0.7	196
161	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. Journal of Hypertension, 2015, 33, 2519-2525.	1.8	42
162	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. Journal of Hypertension, 2015, 33, 1261-1266.	1.8	126

#	Article	IF	Citations
163	Impact of number of prescribed medications on visit-to-visit variability of blood pressure. Journal of Hypertension, 2015, 33, 2359-2367.	1.8	5
164	Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure– and Heart Rate–Independent Manner. JACC: Cardiovascular Interventions, 2015, 8, 972-980.	1.9	42
165	Drug Therapy for the Patient With Resistant Hypertension. Future Cardiology, 2015, 11, 191-202.	0.6	1
166	Obstructive respiratory events and premature atrial contractions after cardioversion. European Respiratory Journal, 2015, 45, 1332-1340.	6.5	43
167	Progression of Kidney Injury and Cardiac Remodeling in Obese Spontaneously Hypertensive Rats: The Role of Renal Sympathetic Innervation. American Journal of Hypertension, 2015, 28, 256-265.	1.0	58
168	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. Hypertension, 2015, 65, 766-774.	4.7	189
169	6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC: Cardiovascular Interventions, 2015, 8, 984-990.	1.9	86
170	Chronische Herzinsuffizienz. Der Internist, 2015, 56, 791-802.	0.4	3
171	Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Science Translational Medicine, 2015, 7, .	8.7	68
172	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clinical Research in Cardiology, 2015, 104, 672-678.	1.5	43
173	Catheter-Based Renal Denervation Reduces Atrial Nerve Sprouting and Complexity of Atrial Fibrillation in Goats. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 466-474.	3.8	69
174	Hochdrucktherapie 2015. Deutsche Medizinische Wochenschrift, 2015, 140, 835-844.	0.1	5
175	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clinical Research in Cardiology, 2015, 104, 1097-1105.	1.5	81
176	Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1. European Heart Journal, 2015, 36, 2219-2227.	2.6	182
177	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. Hypertension, 2015, 65, 193-199.	4.7	117
178	Renal denervation: symply trapped by complexity?. European Heart Journal, 2015, 36, 199-202.	2.6	69
179	Renal nerve ablation. Heart, 2015, 101, 320-328.	2.6	5
180	Witnessed drug intake before planned denervation—Always harmless?. International Journal of Cardiology, 2015, 179, 125-126.	1.6	10

#	Article	IF	Citations
181	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clinical Research in Cardiology, 2015, 105, 364-371.	1.5	59
182	Renal denervation reloaded: where to go from here?. EuroIntervention, 2015, 10, 1135-1137.	2.2	3
183	Catheter-based Renal Denervation for Therapy of Hypertension: Is There a Hope for Its Resurgence?. Hypertension Journal, 2015, 1, 45-50.	0.1	0
184	Effects of Renal Denervation On Atrial Arrhythmogenesis. Future Cardiology, 2014, 10, 813-822.	0.6	5
185	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. Circulation: Cardiovascular Interventions, 2014, 7, 813-820.	3.2	21
186	Response to Letter Regarding Article, “Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?”. Circulation Research, 2014, 115, .	8.6	0
187	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. European Heart Journal, 2014, 35, 2224-2231.	2.6	163
188	Effect of Obstructive Respiratory Events on Blood Pressure and Renal Perfusion in a Pig Model for Sleep Apnea. American Journal of Hypertension, 2014, 27, 1293-1300.	1.0	42
189	Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?. European Heart Journal, 2014, 35, 1706-1711.	2.6	70
190	Improvement of albuminuria after renal denervation. International Journal of Cardiology, 2014, 173, 311-315.	1.6	77
191	Renal Denervation: A Novel Non-pharmacological Approach in Heart Failure. Journal of Cardiovascular Translational Research, 2014, 7, 330-337.	1.3	6
192	Improvements in Left Ventricular Hypertrophy and Diastolic Function Following Renal Denervation. Journal of the American College of Cardiology, 2014, 63, 1916-1923.	0.7	113
193	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, The, 2014, 383, 622-629.	46.9	599
194	Atrial Autonomic Innervation. Journal of the American College of Cardiology, 2014, 63, 215-224.	0.7	147
195	Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?. Circulation Research, 2014, 115, 400-409.	8.6	80
196	Welche kardiale Diagnostik braucht Ihr Hypertoniker?. MMW Fortschritte Der Medizin, 2014, 156, 51-54.	0.0	0
197	Effects of Renal Sympathetic Denervation on Exercise Blood Pressure, Heart Rate, and Capacity in Patients With Resistant Hypertension. Hypertension, 2014, 63, 839-845.	4.7	24
198	Interventionelle Hypertonietherapie bei Diabetes mellitus. Herz, 2014, 39, 325-330.	0.8	0

#	Article	IF	Citations
199	Renal denervation: effects on atrial electrophysiology and arrhythmias. Clinical Research in Cardiology, 2014, 103, 765-774.	1.5	40
200	Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis. Clinical Research in Cardiology, 2014, 103, 743-751.	1.5	78
201	Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension. Current Hypertension Reports, 2014, 16, .	3.5	6
202	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal, 2014, 35, 1752-1759.	2.6	254
203	Innervation Patterns May Limit Response to Endovascular Renal Denervation. Journal of the American College of Cardiology, 2014, 64, 1079-1087.	0.7	121
204	Analyses of drugs stored at home by elderly patients with chronic heart failure. Clinical Research in Cardiology, 2014, 104, 320-327.	1.5	26
205	Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clinical Research in Cardiology, 2014, 104, 380-387.	1.5	40
206	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention, 2014, 9, 1027-1035.	2.2	48
207	Herz und Niere. Herz, 2013, 38, 67-78.	0.8	3
208	Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm, 2013, 10, 1525-1530.	1.9	137
209	Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. International Journal of Cardiology, 2013, 167, 2846-2851.	1.6	122
210	Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. International Journal of Cardiology, 2013, 169, 418-424.	1.6	32
211	Für wen ist sie geeignet?. MMW Fortschritte Der Medizin, 2013, 155, 60-62.	0.0	0
212	Effect of Renal Denervation on Neurohumoral Activation Triggering Atrial Fibrillation in Obstructive Sleep Apnea. Hypertension, 2013, 62, 767-774.	4.7	137
213	Renal Sympathetic Denervation Provides Ventricular Rate Control But Does Not Prevent Atrial Electrical Remodeling During Atrial Fibrillation. Hypertension, 2013, 61, 225-231.	4.7	110
214	Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. Hypertension, 2013, 61, .	4.7	8
215	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.6	140
216	Renal sympathetic denervation: applications in hypertension and beyond. Nature Reviews Cardiology, 2013, 10, 465-476.	25.1	79

#	Article	IF	Citations
217	The Sympathetic Nervous System in Chronic Kidney Disease. Current Hypertension Reports, 2013, 15, 370-376.	3.5	30
218	Renal Denervation in the Treatment of Hypertension. Current Hypertension Reports, 2013, 15, 363-369.	3.5	5
219	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	13.1	242
220	Percutaneous renal denervation: new treatment option for resistant hypertension and more?. Heart, 2013, 99, 1129-1134.	2.6	15
221	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. Journal of Human Hypertension, 2013, 27, 715-720.	1.4	19
222	Treating resistant hypertension: role of renal denervation. Integrated Blood Pressure Control, 2013, , 119.	1.2	12
223	Association of vitamin D status and blood pressure response after renal denervation. Clinical Research in Cardiology, 2013, 103, 41-47.	1.5	22
224	Drug adherence in patients taking oral anticoagulation therapy. Clinical Research in Cardiology, 2013, 103, 173-182.	1.5	43
225	The biophysics of renal sympathetic denervation using radiofrequency energy. Clinical Research in Cardiology, 2013, 103, 337-344.	1.5	37
226	Catheter-based Renal Sympathetic Denervation – Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives. Interventional Cardiology Review, 2013, 8, 118.	1.4	8
227	Application in Hypertension of Renal Sympathetic Denervation – A Review. Interventional Cardiology Review, 2013, 8, 124.	1.4	1
228	Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. EuroIntervention, 2013, 9, 700-708.	2.2	31
229	Renal denervation: expanding the indication. EuroIntervention, 2013, 9, R101-R104.	2.2	7
230	Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias. EuroIntervention, 2013, 9, R110-R116.	2.2	22
231	Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. EuroIntervention, 2013, 9, R122-R126.	2.2	12
232	Physical activity is inversely associated with microalbuminuria in hypertensive patients at high cardiovascular risk: data from I-SEARCH. European Journal of Preventive Cardiology, 2012, 19, 1066-1073.	1.5	10
233	Renal Denervation in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1250-1257.	0.2	350
234	Renal Sympathetic Denervation Suppresses Postapneic Blood Pressure Rises and Atrial Fibrillation in a Model for Sleep Apnea. Hypertension, 2012, 60, 172-178.	4.7	225

#	Article	IF	Citations
235	Blood pressure and heart rate predict outcome in patients acutely admitted with suspected myocarditis without previous heart failure. Journal of Hypertension, 2012, 30, 1217-1224.	1.8	14
236	311 FEASIBILITY OF CATHETER-BASED RENAL DENERVATION AND EFFECTS ON SYMPATHETIC NERVE ACTIVITY AND BLOOD PRESSURE IN PATIENTS WITH END-STAGE RENAL DISEASE. Journal of Hypertension, 2012, 30, e91-e92.	1.8	1
237	Effects of Renal Sympathetic Denervation on Arterial Stiffness and Central Hemodynamics in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2012, 60, 1956-1965.	0.7	150
238	Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2012, 59, 901-909.	0.7	488
239	Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. Clinical Research in Cardiology, 2012, 101, 761-766.	1.5	16
240	Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats. Journal of Translational Medicine, 2012, 10, .	4.8	24
241	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension, 2012, 60, 419-424.	4.7	302
242	Inadequate Reporting of Concomitant Drug Treatment in Cardiovascular Interventional Head-to-Head Trials. Clinical Cardiology, 2012, 35, 255-256.	1.5	7
243	Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2011, 9, 729-744.	1.2	15
244	Variability of ventricular repolarization during hypoglycemia. International Journal of Cardiology, 2011, 149, 285-286.	1.6	1
245	Sympatho-renal axis in chronic disease. Clinical Research in Cardiology, 2011, 100, 1049-1057.	1.5	162
246	Renale Sympathikusdenervation. Herz, 2011, 36, 8-11.	0.8	5
247	Device-Based Antihypertensive Therapy. Circulation, 2011, 123, 209-215.	13.1	146
248	Virus serology in patients with suspected myocarditis: utility or futility?. European Heart Journal, 2011, 32, 897-903.	2.6	197
249	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clinical Research in Cardiology, 2011, 101, 63-67.	1.5	220
250	Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010. Clinical Research in Cardiology, 2010, 99, 679-692.	1.5	2
251	The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. International Journal of Cardiology, 2010, 145, 172-176.	1.6	72
252	The vulnerable myocardium: long-QT syndrome in Tako-Tsubo cardiomyopathy. Clinical Research in Cardiology, 2009, 98, 409-411.	1.5	3

#	Article	IF	Citations
253	Neue Methode. Kardiologe, 2009, 3, 474-479.	0.2	3
254	Treatment Strategies for Resistant Arterial Hypertension. Deutsches Ärzteblatt International, 0, , .	0.1	33
255	In Reply. Deutsches Ärzteblatt International, 0, , .	0.1	0
256	“Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. Deutsches Ärzteblatt International, 0, , .	0.1	3
257	Title is missing!. , 0, .		1
258	Impact of centrally acting sympatholytic agents on the blood pressure response to renal denervation. Journal of Hypertension, 0, 44, 592-599.	1.8	0
259	26-A-15422-ACC REDUCING HYPERTENSIVE URGENCY WITH RADIOFREQUENCY RENAL DENERVATION THROUGH THREE YEARS: INSIGHTS FROM THE SPYRAL HTN-ON AND OFF MED TRIALS. Journal of the American College of Cardiology, 0, 87, A206-A207.	0.7	0
260	Right ventricular to pulmonary artery coupling and clinical outcomes after interatrial shunting in heart failure: exploratory analysis of the PRELIEVE study. ESC Heart Failure, 0, 13, .	1.9	0